SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare gains on launching Zolmitriptan in US market

17 May 2013 Evaluate

Cadila Healthcare is currently trading at Rs. 841.75, up by 5.95 points or 0.71% from its previous closing of Rs. 835.80 on the BSE.

The scrip opened at Rs. 835.80 and has touched a high and low of Rs. 845.00 and Rs. 835.80 respectively.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 964.00 on 12-Sep-2012 and a 52 week low of Rs. 705.05 on 04-Jun-2012.

Last one week high and low of the scrip stood at Rs. 846.80 and Rs. 771.00 respectively. The current market cap of the company is Rs. 17,234.00 crore.

The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 16.53 % and 8.68 % respectively.

Cadila Healthcare has declared the first day launch of Zolmitriptan orally disintegrating tablets upon receiving the final approval from the US Food and Drug Administrator (USFDA). The drug is used in the treatment of migraine, has an estimated sale of $175 million in 2012 as per IMS.

The company would market the product in the strengths of 2.5 mg and 5mg in the US market. The group now has 79 approvals and has so far filed 173 ANDAs since the commencement of the filing process in FY 2003-04.

The flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

939.20 3.20 (0.34%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×